Variable
|
Overall survival
|
Cancer specific survival
|
---|
HR (95% Confidence Limit)
|
P value
|
HR (95% Confidence Limit)
|
P value
|
---|
Age group
|
< =60
|
Reference
| |
Reference
| |
61–70
|
1.1 (1 to 1.1)
|
0.0005
|
1.1 (1 to 1.1)
|
0.0061
|
71–80
|
1.1 (1 to 1.1)
|
0.0012
|
1 (1 to 1.1)
|
0.2039
|
> 80
|
1.1 (1.1 to 1.2)
|
< 0.0001
|
1.1 (1 to 1.1)
|
0.0037
|
Sex
|
Female
|
Reference
| |
Reference
| |
Male
|
1.2 (1.2 to 1.2)
|
< 0.0001
|
1.2 (1.2 to 1.2)
|
< 0.0001
|
Year of diagnosis
|
1 (1 to 1)
|
0.0012
|
1 (1 to 1)
|
0.1635
|
CCI score
|
0
|
Reference
| |
Reference
| |
1
|
1 (0.9 to 1)
|
0.2999
|
1 (0.9 to 1)
|
0.145
|
> 1
|
1.2 (1.1 to 1.2)
|
< 0.0001
|
1.2 (1.1 to 1.2)
|
< 0.0001
|
Cardiovascular disease
|
Yes
|
Reference
| |
Reference
| |
No
|
1.1 (1.1 to 1.2)
|
< 0.0001
|
1.1 (1.1 to 1.1)
|
< 0.0001
|
Histology
|
Adenocarcinoma
|
Reference
| |
Reference
| |
SCC
|
1.1 (1 to 1.1)
|
0.0182
|
1 (1 to 1.1)
|
0.2506
|
SCLC
|
1.6 (1.5 to 1.7)
|
< 0.0001
|
1.6 (1.5 to 1.7)
|
< 0.0001
|
Carcinoid/LCNE
|
0.7 (0.7 to 0.8)
|
< 0.0001
|
0.8 (0.7 to 0.9)
|
< 0.0001
|
Large cell ca
|
1.3 (1.1 to 1.4)
|
0.0011
|
1.3 (1.1 to 1.5)
|
0.0005
|
Others
|
1.2 (1.2 to 1.3)
|
< 0.0001
|
1.2 (1.2 to 1.3)
|
< 0.0001
|
T stage
|
T0
|
Reference
| |
Reference
| |
T1
|
1.3 (1 to 1.6)
|
0.0394
|
1.1 (0.9 to 1.4)
|
0.2457
|
T2
|
1.8 (1.5 to 2.3)
|
< 0.0001
|
1.8 (1.4 to 2.2)
|
< 0.0001
|
T3
|
2.5 (2 to 3.1)
|
< 0.0001
|
2.4 (1.9 to 3)
|
< 0.0001
|
T4
|
2.6 (2.1 to 3.2)
|
< 0.0001
|
2.5 (2 to 3.1)
|
< 0.0001
|
Unknown
|
1.8 (1.4 to 2.2)
|
< 0.0001
|
1.7 (1.4 to 2.2)
|
< 0.0001
|
N stage
|
N0
|
Reference
| |
Reference
| |
N1
|
1.4 (1.3 to 1.5)
|
< 0.0001
|
1.5 (1.4 to 1.6)
|
< 0.0001
|
N2
|
1.8 (1.7 to 1.8)
|
< 0.0001
|
1.9 (1.8 to 1.9)
|
< 0.0001
|
N3
|
1.8 (1.7 to 1.9)
|
< 0.0001
|
1.9 (1.8 to 2)
|
< 0.0001
|
Unknown
|
1.6 (1.5 to 1.7)
|
< 0.0001
|
1.7 (1.5 to 1.8)
|
< 0.0001
|
M stage
|
M0
|
Reference
| |
Reference
| |
M1
|
1.9 (1.8 to 1.9)
|
< 0.0001
|
2 (1.9 to 2.1)
|
< 0.0001
|
Unknown
|
0.9 (0.8 to 1)
|
0.2007
|
0.9 (0.8 to 1.1)
|
0.2776
|
Lateral
|
Bilateral
|
Reference
| |
Reference
| |
Left
|
1.3 (1.1 to 1.5)
|
0.0001
|
1.3 (1.1 to 1.5)
|
0.0014
|
Right
|
1.3 (1.2 to 1.5)
|
< 0.0001
|
1.3 (1.1 to 1.5)
|
0.0005
|
Unknown
|
2 (1.7 to 2.4)
|
< 0.0001
|
1.9 (1.6 to 2.3)
|
< 0.0001
|
Surgery type
|
Pneumonectomy
|
Reference
| |
Reference
| |
Lobectomy or segmental
|
0.7 (0.6 to 0.9)
|
0.0002
|
0.6 (0.5 to 0.8)
|
< 0.0001
|
Non-surgery
|
2.8 (2.4 to 3.3)
|
< 0.0001
|
2.7 (2.3 to 3.3)
|
< 0.0001
|
Chemotherapy
|
No
|
Reference
| |
Reference
| |
Yes
|
0.4 (0.4 to 0.4)
|
< 0.0001
|
0.4 (0.4 to 0.4)
|
< 0.0001
|
Radiation
|
No
|
Reference
| |
Reference
| |
Yes
|
0.6 (0.6 to 0.7)
|
< 0.0001
|
0.6 (0.6 to 0.7)
|
< 0.0001
|
Surgery institution type
|
Academic
|
Reference
| |
Reference
| |
Community
|
1 (1 to 1.1)
|
0.44
|
1 (1 to 1.1)
|
0.069
|
Driving time (hours)
|
1
|
Reference
| |
Reference
| |
2
|
1 (1 to 1.1)
|
0.5613
|
1 (1 to 1.1)
|
0.4693
|
3
|
0.9 (0.8 to 1)
|
0.0215
|
0.9 (0.8 to 1)
|
0.0073
|
Zone name
|
Calgary
|
Reference
| |
Reference
| |
Central
|
1.1 (1 to 1.1)
|
0.004
|
1.1 (1 to 1.1)
|
0.03
|
Edmonton
|
1.1 (1 to 1.1)
|
< 0.0001
|
1.1 (1.1 to 1.1)
|
< 0.0001
|
North
|
1.2 (1.1 to 1.3)
|
< 0.0001
|
1.2 (1.1 to 1.3)
|
< 0.0001
|
South
|
1.2 (1.1 to 1.3)
|
< 0.0001
|
1.2 (1.1 to 1.3)
|
< 0.0001
|
Education levela
|
< = 80%
|
Reference
| |
Reference
| |
> 80%
|
1 (1 to 1)
|
0.3769
|
1 (1 to 1)
|
0.5999
|
Income level
|
< = 46 k
|
Reference
| |
Reference
| |
> 46 k
|
1 (1 to 1)
|
0.9992
|
1 (1 to 1)
|
0.8051
|
- CCI Charlson’s comorbidity index, SCC Squamous cell cancer, SCLC Small cell lung cancer, LCNE Large Cell Neuroendocrine tumor. a80% of residents have high school and above level of education in the neighborhood